Acute BRCAness induction and AR pathway blockage through CDK12/7/9 degradation enhances PARP inhibitor sensitivity in prostate cancer.

Saved in:
Bibliographic Details
Title: Acute BRCAness induction and AR pathway blockage through CDK12/7/9 degradation enhances PARP inhibitor sensitivity in prostate cancer.
Authors: Gui F; Department of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Jiang B; Department of Cancer Biology, Dana-Farber Cancer Institute and Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Jiang J; Department of Cancer Biology, Dana-Farber Cancer Institute and Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., He Z; Department of Cancer Biology, Dana-Farber Cancer Institute and Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Tsujino T; Department of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.; Department of Urology, Osaka Medical and Pharmaceutical University, Takatsuki, Japan., Takai T; Department of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.; Department of Urology, Osaka Medical and Pharmaceutical University, Takatsuki, Japan., Arai S; Department of Medicine and Cancer Center, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.; Department of Urology, Gunma University Graduate School of Medicine, Gunma, Japan., Pana C; Goethe University Frankfurt, University Hospital, Department of Urology, Frankfurt am Main, Germany., Köllermann J; Goethe University Frankfurt, University Hospital, Dr. Senckenberg Institute of Pathology, Frankfurt am Main, Germany., Bradshaw GA; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA., Eisert R; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA., Kalocsay M; Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Fassl A; Goethe University Frankfurt, University Hospital, Department of Urology, Frankfurt am Main, Germany., Balk SP; Department of Medicine and Cancer Center, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA., Kibel AS; Department of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Jia L; Department of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Source: Science advances [Sci Adv] 2025 Apr 25; Vol. 11 (17), pp. eadu0847. Date of Electronic Publication: 2025 Apr 23.
Publication Type: Journal Article
Journal Info: Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 101653440 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2375-2548 (Electronic) Linking ISSN: 23752548 NLM ISO Abbreviation: Sci Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2375-2548
DOI:10.1126/sciadv.adu0847